Multicenter evaluation of complex urinary diversion for renal transplantation: outcomes of complex surgical solutions.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
17 Apr 2024
Historique:
received: 01 08 2023
accepted: 18 11 2023
medline: 18 4 2024
pubmed: 17 4 2024
entrez: 17 4 2024
Statut: epublish

Résumé

An abnormal lower urinary tract poses significant challenges for transplant surgeons. Besides the ureteral anastomosis to an ileal conduit, there are diverse complex reconstructive solutions. Due to its rarity, standardization and teaching of complex urinary diversion is extremely difficult. The indications and outcomes of complex urinary diversions after kidney transplantation (KT) were retrospectively investigated at eight urologic transplant centers including a current follow-up. Of 37 patients with 21 (56%) males, vesicoureteral reflux (24%), spina bifida (22%), and glomerulonephritis (12%) were the most common causes of terminal renal failure. In 30 (81%) patients, urinary diversion was performed before KT, at a median of 107.5 (range, 10; 545) months before. Transplantations were held at a median patient age of 43 (10; 68) years, including six (16%) living donations. Urinary diversion was modified during 12 (32%) transplantations. After KT, the ileal conduit was the most common incontinent urinary diversion in 25 (67%) patients; a Mainz pouch I and bladder augmentation were the most frequent continent diversions (each n = 3). At a median follow-up of 120 months (range 0; 444), 12 (32%) patients had a graft failure with a 5-year graft survival of 79% (95%CI 61; 90). The median overall survival was 227 months (168; 286) and the 5-year overall survival 89% (69.3; 96.4). The mid-term kidney transplant function with complex urinary diversion appears to be comparable to transplants with regular urinary diversions. Hence, complex urinary diversion should always be considered as a surgical option, even during transplantation, if necessary.

Identifiants

pubmed: 38630278
doi: 10.1007/s00345-024-04934-1
pii: 10.1007/s00345-024-04934-1
pmc: PMC11023965
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

239

Investigateurs

Luka Flegar (L)
Johannes Huber (J)
Juliane Putz (J)
Christian Thomas (C)
Hendrik Apel (H)
Bernd Wullich (B)
Frank Friedersdorff (F)
Manuel Ritter (M)
Karoline Kernig (K)
Karl Weigand (K)
Hans Heynemann (H)
Michael Stöckle (M)
Philip Zeuschner (P)

Informations de copyright

© 2024. The Author(s).

Références

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E7-E11
pubmed: 26858788
Int J Urol. 2011 Mar;18(3):185-93
pubmed: 21299639
J Urol. 1971 Jul;106(1):133-9
pubmed: 4935504
Transplantation. 2000 Dec 27;70(12):1713-7
pubmed: 11152102
Adv Chronic Kidney Dis. 2011 Sep;18(5):348-54
pubmed: 21896376
Transplant Proc. 2009 Jul-Aug;41(6):2382-4
pubmed: 19715926
Transplantation. 2005 Nov 27;80(10):1435-40
pubmed: 16340788
J Am Med Assoc. 1956 Jan 28;160(4):277-82
pubmed: 13278189
J Urol. 2001 Jun;165(6 Pt 2):2265-8
pubmed: 11371960
BJU Int. 2009 Jun;103(11):1555-60
pubmed: 19076129
Transplant Proc. 2001 Jun;33(4):2493-4
pubmed: 11406224
Croat Med J. 2019 Dec 31;60(6):545-551
pubmed: 31894920
Am J Transplant. 2010 Apr;10(4 Pt 2):961-72
pubmed: 20420646
Nephrol Dial Transplant. 1998 Aug;13(8):2065-9
pubmed: 9719166
BJU Int. 2000 Jul;86(1):28-31
pubmed: 10886078
J Urol. 2003 Nov;170(5):1727-30
pubmed: 14532763
Nephrol Dial Transplant. 2012 Apr;27(4):1663-71
pubmed: 21926404
Transplant Proc. 2013 May;45(4):1661-6
pubmed: 23726643
Clin Transplant. 2018 Jun;32(6):e13260
pubmed: 29656398
Nephrol Dial Transplant. 1999 Dec;14(12):2937-40
pubmed: 10570101
Urology. 2009 Feb;73(2):380-5
pubmed: 19022489
Eur Urol. 2022 Sep;82(3):336-337
pubmed: 35717360
World J Urol. 2022 Jan;40(1):301-302
pubmed: 33175209
J Urol. 1998 Jun;159(6):2110-3
pubmed: 9598551
Lancet. 1966 Jan 29;1(7431):222-6
pubmed: 4159068

Auteurs

Luka Flegar (L)

Department of Urology, Philipps-University Marburg, Baldinger Street, 35043, Marburg, Germany. luka.flegar@uk-gm.de.

Johannes Huber (J)

Department of Urology, Philipps-University Marburg, Baldinger Street, 35043, Marburg, Germany.

Juliane Putz (J)

Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Christian Thomas (C)

Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Hendrik Apel (H)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Transplant Center Erlangen-Nürnberg, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Bernd Wullich (B)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Transplant Center Erlangen-Nürnberg, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Frank Friedersdorff (F)

Department of Urology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Guido Fechner (G)

Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany.

Manuel Ritter (M)

Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany.

Karoline Kernig (K)

Department of Urology, University Rostock, Rostock, Germany.

Karl Weigand (K)

Department of Urology, University Hospital Halle (Saale), Halle (Saale), Germany.

Hans Heynemann (H)

Department of Urology, University Hospital Halle (Saale), Halle (Saale), Germany.

Michael Stöckle (M)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Philip Zeuschner (P)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH